AstraZeneca (LSE:AZN) recently announced phase III trial results for Breztri Aerosphere, its triple-combination asthma ...

Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents with uncontrolled asthma in two phase 3 trials, according to a press ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE ...

AstraZeneca announced on Friday that its inhaled triple-combination therapy ‘Breztri Aerosphere’ met all primary endpoints in ...

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

AstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE ...